옵션 체인은 다양한 행사가격과 만기일에 대한 TOP Finl Gr의 주식 옵션 주요 데이터를 보여줍니다. 트레이더들은 이 정보를 사용하여 잠재적 거래를 분석하고 TOP Finl Gr에 대한 시장 심리를 평가합니다..

TOP Finl Gr (NASDAQ:TOP) 주식, 옵션 체인

TOP Finl Gr

TOP Financial Group Ltd is an online brokerage firm in Hong Kong specializing in trading local and overseas equities, futures, and options products. The Company generates brokerage commission income by enabling its customers to trade on multiple exchanges present globally. The company operates in only one segment which is the futures brokerage service.

Asia

Fintech news covering the emerging Financial Technology services sector

Fintech

News

Global

After-Hours Center

Movers

FUTU

TIGR

탑 파이낸셜 그룹(NASDAQ:TOP)의 주식은 중국의 경기 부양책 발표 이후 중국 기반 기업들의 주가 상승이 계속되는 가운데 높은 거래량으로 60% 이상 급등했다.

홍콩 기반 금융 회사인 탑 파이낸셜의 주식이 수요일 60% 이상 급등: 무슨 일이?

TOP Financial Group Limited - Class A Ordinary Shares

TOP Financial Group Ltd

Topcon Corp

Toppoint Holdings Inc

TOPPAN HLDGS S/ADR by TOPPAN HOLDINGS INC.

Toppan Holdings Inc

TOP Ships Inc

iShares Trust iShares Top 20 U.S. Stocks ETF

TOPAZ RESOURCES INC by Topaz Resources, Inc.

Topaz Resources Inc

OPTT

Ocean Power Technologies Announces Successful Demonstration Of Defense And Security Capabilities At NAVDEX. Showcasing WAM-V Unmanned Surface Vehicles, Next Generation Powerbuoy, And AI Capable Merrows

Manulife Financial Corporation ("Manulife") announced today that it has&nbsp;entered into an automatic share repurchase plan (the "automatic plan") under which its designated broker will repurchase Manulife's common shares pursuant to its previously announced normal course issuer bid ("NCIB"). The actual number of common shares purchased under the automatic plan, the timing of such purchases and the price at which common shares are purchased will depend upon future market conditions. The automatic plan, which was pre-cleared by the TSX, provides for the potential repurchase of common shares at any time, including when Manulife ordinarily would not be active in the market due to its own internal trading blackout periods, insider trading rules, or otherwise.

Buybacks

Manulife Initiates Automatic Share Repurchase Plan Under Normal Course Issuer Bid; No Terms Disclosed

Stephens &amp; Co. analyst Sudan Loganathan maintains ADC Therapeutics (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ADCT#NYSE">ADCT</a>) with a Overweight and raises the price target from $6 to $8.

Price Target

Analyst Ratings

ADCT

Stephens & Co. Maintains Overweight on ADC Therapeutics, Raises Price Target to $8

Piper Sandler analyst Derek Podhaizer maintains Solaris Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SEI#NYSE">SEI</a>) with a Overweight and raises the price target from $37 to $50.

Piper Sandler Maintains Overweight on Solaris Energy, Raises Price Target to $50

On Friday, Co-Diagnostics, Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CODX#NASDAQ">CODX</a>) withdrew its FDA 510(k) application for its Co-Dx PCR COVID-19 Test on the PCR Pro in favor of submitting an enhanced version of the test <a target="_blank" href="https://www.benzinga.com/pressreleases/25/02/n43895005/co-diagnostics-inc-announces-intention-to-submit-enhanced-version-of-covid-19-test-to-fda-for-510-" rel="noreferrer noopener">for 510(k) clearance</a>.
The company&#8217;s decision to withdraw the submission was based on discussions with the FDA regarding the ability to detect a potential deterioration of one component of the test related to shelf-life stability.
Also Read: <a target="_blank" href="https://www.benzinga.com/25/02/43890231/why-is-cancer-focused-exelixis-stock-trading-higher-on-friday" rel="noreferrer noopener">Why Is Cancer-Focused Exelixis Stock Trading Higher On Friday?</a>
Following dialogue with the FDA and exploring the various courses of action available, Co-Dx has determined that the best long-term solution would be to submit an enhanced version of the test to address the matter raised in the 510(k) review process.&nbsp;
After collecting clinical evaluation data to support the new test&#8217;s performance, the company plans to submit the next iteration of the Co-Dx PCR COVID-19 test for 510(k) OTC clearance.
A new submission also allows the company to incorporate more recent&nbsp;Co-Dx PCR platform developments into the COVID-19 test, which Co-Dx believes will help create greater operational and manufacturing efficiencies. For example, it could consolidate manufacturing processes to utilize the next generation of test kits and instruments across all tests on the at-home and point-of-care platform.
The Co-Dx PCR COVID-19 test is expected to be followed by additional tests for tuberculosis, upper-respiratory multiplex, and a multiplex HPV test, among others.
Price Action: CODX stock is down 14.9% at $0.60 during the premarket session on last check Monday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/government/regulations/25/02/43894411/volkswagens-audi-to-grow-north-american-production-report" target="_blank" rel="noreferrer noopener">Volkswagen&#8217;s Audi To Grow North American Production: Report</a></li>
</ul>
Photo by Horth Rasuer via Shutterstock

Penny Stocks

Health Care

Trading Ideas

General

CODX

Penny Stock Co-Diagnostics Withdraws FDA Application For COVID-19 Test, Plans To Submit Enhanced Version

The company's board of directors also authorized an additional share repurchase program of $1.5 billion of the company's common stock. The authorization is effective immediately and is additive to the previous $1.5 billion program authorized on November 3, 2023, which had $194 million remaining authorized and available for repurchase on December 31, 2024.
Since 2017, the company has repurchased $6.7 billion of its common stock, representing 41 percent of its outstanding shares, and has paid cash dividends of $1.7 billion through December 31, 2024. In the last five years, the company continued its meaningful strategic growth, investing $7.1 billion in capital investments and acquisitions, while maintaining a best-in-class, after-tax-return-on-invested capital of 24 percent.&nbsp;

STLD

Steel Dynamics Authorizes An Additional Share Repurchase Program Of $1.5B Of The Company's Common Stock

Biotech

BACK

Ignite Proteomics, Subsidiary Of IMAC Holdings, Announces MHC-II Expression As Superior Predictor For Pembrolizumab Response Compared To PD-L1 Ahead Of NCCN Conference

Wolfe Research analyst Nigel Coe upgrades Carrier Global (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CARR#NYSE">CARR</a>) from Peer Perform to Outperform and maintains the price target from $80 to $80.

Upgrades

CARR

Wolfe Research Upgrades Carrier Global to Outperform, Maintains Price Target to $80

<figure class="wp-block-image size-full"><img loading="lazy" decoding="async" width="900" height="600" src="https://contributor-assets.benzinga.com/wp-content/uploads/2025/02/24103358/AAC.jpeg" alt="" class="wp-image-6312" srcset="https://contributor-assets.benzinga.com/wp-content/uploads/2025/02/24103358/AAC.jpeg 900w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/02/24103358/AAC-300x200.jpeg 300w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/02/24103358/AAC-768x512.jpeg 768w" sizes="(max-width: 900px) 100vw, 900px" /></figure>
Surging smartphone sales helped to power the acoustic component supplier to turbocharged profit growth last year, but the stock failed to rally strongly on the news

<h4 class="wp-block-heading">Key Takeaways:</h4>
<ul>
<li>AAC Technologies said it expects to report that its profit rose as much as 145% last year</li>
<li>The acoustic component maker said car acoustics are expected to become a future growth driver</li>
</ul>
Talk about big noises falling on deaf ears.
On Feb. 13, acoustic component supplier AAC Technologies Holdings Inc. (2018.HK) made <a href="https://www1.hkexnews.hk/listedco/listconews/sehk/2025/0213/2025021300995.pdf">an announcement</a> that should have been music to investor ears, saying after the market closed it would report that its profit more than doubled last year. The next day, which just happened to be Valentine's Day, brokerage UOB Kay Hian sharply raised its target price for the company to HK$48 from HK$38.10, while maintain its "hold" rating.
While the benchmark Hang Seng Composite Index logged an impressive 805-point Valentine's Day jump that day, AAC's shares attracted less love from investors, rising by a relatively modest 3% to close at exactly HK$48. The stock is up 45% over the last six months, amid a broader rally that has seen the Hang Seng Technology Index rise by an even bigger 70% over that time. But the muted response to the positive profit alert could show AAC's own rally may be running out of steam at around the HK$50 level.
Having made it to UOB Kay Hian's new target price, the new question for AAC now becomes whether there's room for any future upside, or if the stock may have peaked for now.
<h4 class="wp-block-heading">The $26-billion company</h4>
AAC Technologies once used its cutting-edge acoustic technology to win over major clients, including the likes of Apple. The company rode the smartphone boom for most of the 2010s to become a constituent stock of Hong Kong's Hang Seng Index, as its market capitalization peaked as high as HK$205.3 billion ($26.4 billion) in 2017.
But smartphone saturation and growing competition finally caught up with AAC, sending it into a downward spiral. Its shares lost more than 90% of their value, sending its market value to less than HK$13 billion at its low. Following several years at rock bottom, the company has finally begun to find its way past this darker period in its history.
According to its pre-Valentine's Day announcement, AAC expects to report a 2024 profit of between 1.7 billion yuan ($234 million) and 1.82 billion yuan, up 130% to 145% year-on-year. It attributed the rebound to a recovering global smartphone market and its own improved operations. It also completed its acquisition of Acoustics Solutions International B.V., a supplier of acoustic components and audio systems, during the year, providing a booster to its automotive business.
<h4 class="wp-block-heading">Big share gains</h4>
The big profit jump adds to previous signals that AAC's comeback isn't just a fluke. The company's profit actually grew by an even larger 257% year-on-year in the first half of 2024 to 537 million yuan. Calculations using the latest profit forecast show the company's profit was at least 1.16 billion yuan in the second half of the year, more than double the first-half profit, showing the business continued gaining momentum in the final six months of 2024.
In fact, AAC Technologies' share price has already risen strongly as its comeback gains steam, up 180% over the past year.
But is there further room for even greater gains? Let's explore that question further. After all, the company once had revenue as high as 21.1 billion yuan, and a net profit of 5.33 billion yuan at its peak in 2017. Thus, while the 2024 profit is up sharply from 2023, it's still a far cry from the company's historic highs.
<h4 class="wp-block-heading">Slowing smartphone market</h4>
A slowdown in the smartphone market could be a major spoiler for AAC's young comeback. Global smartphone shipments totaled 1.24 billion units last year, up 6.4% from 2023, according to data tracking firm IDC. But fourth-quarter shipments rose by a far smaller 2.4% year-on-year to 332 million units, and IDC expects the market to continue growing at a slower pace this year.
Fierce competition, which has led customers to pit their suppliers against each other in a quest for lower prices, has also made it nearly impossible for AAC to regain the high margins it once enjoyed. The company boasted a gross margin as high as 41.4% at its height back in 2017. But that figure has been nearly halved to just 21.5% in the first half of 2024. UOB Kay Hian forecasts the company's gross margin will stay at current levels for now, predicting figures of 23.1%, 23.7% and 24.5% from 2024 to 2026, respectively. So, a return to fat profits of earlier years looks unlikely anytime soon.
Outside acoustics, AAC has also been trying to get a toehold in the optical business. Revenue from its optical division grew 24.9% to 2.21 billion yuan in the first half of last year, accounting for nearly 20% of the company's total. But optical components have a far worse gross margin than acoustics, at just 4.7%, limiting the profit potential for that part of the business.
<h4 class="wp-block-heading">Overvalued?</h4>
Seeking to branch out beyond smartphones, AAC has been keen to expand its car acoustics business in recent years. It made a major move in that direction with last year's acquisition of Premium Sound Solutions (PSS), which was part of the previously mentioned Acoustics Solutions International B.V. deal. But its status as a relative latecomer to car acoustics will make it difficult for AAC to catch up with more veteran competitors like&nbsp;Sonavox&nbsp;and&nbsp;Harman, as well as&nbsp;Goertek&nbsp;(002241.SZ), which bought Dynaudio.
All this shows there's probably still some room for AAC to keep growing, though it's unlikely to return to its previous glory days anytime soon. After all, the era of breakneck growth in the early days of smartphones looks increasingly like a distant memory. The company's newer businesses certainly won't bring in big profits over the short-term, as it still needs time to build its credibility in those areas.
Accordingly, investors shouldn't be overly optimistic about the potential for more big gains for AAC's stock, especially after its recent run-up. The company's 2024 profit forecast gives it a sizable price-to-earnings (P/E) ratio of about 31 times. That's slightly head of the 28 times for Shenzhen-listed&nbsp;Luxshare&nbsp;(002475.SZ), even though Luxshare has a higher profit and market capitalization and Shenzhen-listed shares generally trade at higher multiples to their Hong Kong counterparts. Against that kind of backdrop, some may even begin to question whether AAC's stock may be overvalued after its yearlong rally.

Earnings

Equities

AAC Technologies' Big Comeback Already Priced Into Stock?

Piper Sandler analyst Matt O'Brien initiates coverage on Beta Bionics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BBNX#NASDAQ">BBNX</a>) with a Overweight rating and announces Price Target of $26.

Initiation

BBNX

Piper Sandler Initiates Coverage On Beta Bionics with Overweight Rating, Announces Price Target of $26

FOXO Technologies Inc.&nbsp;(NYSE American:&nbsp;FOXO)&nbsp;(the "Company or FOXO"), announces that it has executed a non-binding acquisition agreement for two assisted living facilities in Florida.
One facility has 129 units, and the second facility has 137 units. The purchase price for each facility is expected to be $30 million, a portion of which is milestone-based. The parties aim to complete definitive agreements withing 60 days, Closing is expected to occur between 60 and 120 days after completion of definitive agreements and is subject to a number of closing conditions, including satisfactory due diligence and financing.

FOXO

Foxo Technologies Announces Execution Of A Non-Binding Acquisition Agreement For Two Assisted-Living Facilities In Florida For A Total Consideration Of $60M

ImmunoPrecise Antibodies (the "Company" or "IPA") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IPA#NASDAQ">IPA</a>), an AI-driven biotherapeutic research and technology company, is pleased to announce key leadership updates, including the appointment of Kamil Isaev to its Board of Directors and Joseph Scheffler as Interim Chief Financial Officer (CFO). Additionally, IPA announces the planned departure of Chris Buyse from the Board of Directors.

Management

ImmunoPrecise Antibodies Announces The Appointment Of Kamil Isaev To Its Board Of Directors And Joseph Scheffler As Interim Chief Financial Officer

Dividends

Steel Dynamics Announces 9% Dividend Increase From $0.46 To $0.50 Per Share For Q1 2025, Payable April 11

Scaled Investment Platform Expands Apollo's Origination Capabilities in Residential and Industrial Real Estate
Bridge Manages $50 Billion of High-Quality AUM in Complementary Sectors Aligned with Apollo's Long-Term Growth Strategy
NEW YORK and SALT LAKE CITY, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Apollo (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/APO#NYSE">APO</a>) and Bridge Investment Group Holdings Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BRDG#NYSE">BRDG</a>) ("Bridge" or the "Company") today announced they have entered into a definitive agreement for Apollo to acquire Bridge in an all-stock transaction with an equity value of approximately $1.5 billion.

Asset Sales

BRDG

Apollo Has Entered Into A Definitive Agreement To Acquire Bridge In An All-Stock Transaction With An Equity Value Of ~$1.5B

reAlpha Tech Corp. ("reAlpha") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AIRE#NASDAQ">AIRE</a>), a real estate technology company developing and commercializing artificial intelligence ("AI") technologies, today announced the acquisition of GTG Financial, Inc. ("GTG Financial"), a mortgage brokerage company founded by Glenn Groves, a U.S. Marine and industry leader. GTG Financial is licensed to operate in seven U.S. states, including California, which will expand reAlpha's geographic footprint to a total of 28 U.S. states and strengthen its operational capacity.

AIRE

reAlpha Acquires GTG Financial, Inc.; No Financial Terms Disclosed

Celularity Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/celu#NASDAQ">CELU</a>) ("Celularity" or the "Company"), a cellular and regenerative medicine company, today announced that it has entered into a Master Services Collaboration Agreement with BlueSphere Bio, Inc.
Celularity Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CELU#NASDAQ">CELU</a>) ("Celularity" or the "Company"), a cellular and regenerative medicine company, today announced that it has entered into a Master Services Collaboration Agreement with BlueSphere Bio, Inc. (BSB) covering manufacturing activities for certain BSB cell therapy products. This collaboration is the second of its kind for Celularity and demonstrates the Company's ability to leverage its world class cGMP manufacturing infrastructure and deep expertise to attract clients like BSB, who are seeking differentiated alternatives to manufacture their therapeutic products in an ever-changing landscape. This collaboration further evidences the revenue generating potential of Celularity's assets.
The Collaboration Agreement will initially focus on the production of BSB's novel T cell receptor (TCR) T cell therapies using the technical and manufacturing capabilities at Celularity's Florham Park, NJ, cGMP-ready facility. This collaboration will extend to all aspects of cell therapy manufacturing including Chemistry, Manufacturing and Controls (CMC), Quality Assurance and Quality Control. As part of this Collaboration, Celularity will dedicate staff and a small portion of its 37,000 square foot commercial manufacturing footprint. In coordination with&nbsp;Celularity management,&nbsp;BSB and its team will have oversight over production of its second cell therapy product for the treatment of Acute Myelogenous Leukemia (AML) both in the U.S. and abroad.

CELU

Celularity Announces Master Services Collaboration With BlueSphere Bio For Manufacturing BSB Cell Therapy Products, Utilizing Florham Park cGMP Facility; Project Involves 37K Sq Ft Space, Focus On TCR T Cell Therapy For AML

<h3>Gainers</h3>
<table>
<thead>
<tr>
<th>Symbol</th>
<th>Name</th>
<th align="right">Price</th>
<th align="right">Change ($)</th>
<th align="right">Change (%)</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLF#NYSE">XLF</a>)</td>
<td>SPDR Select Sector Fund - Financial</td>
<td align="right">51.1400</td>
<td align="right">0.390</td>
<td align="right">0.76</td>
<td>253.5K</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLE#NYSE">XLE</a>)</td>
<td>SPDR Select Sector Fund - Energy Select Sector</td>
<td align="right">91.4468</td>
<td align="right">0.517</td>
<td align="right">0.56</td>
<td>4.9K</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLB#NYSE">XLB</a>)</td>
<td>Materials Select Sector SPDR</td>
<td align="right">88.5000</td>
<td align="right">0.430</td>
<td align="right">0.48</td>
<td>336</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLI#NYSE">XLI</a>)</td>
<td>SPDR Select Sector Fund - Industrial</td>
<td align="right">135.4200</td>
<td align="right">0.580</td>
<td align="right">0.43</td>
<td>1.5K</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLU#NYSE">XLU</a>)</td>
<td>SPDR Select Sector Fund - Utilities</td>
<td align="right">80.6200</td>
<td align="right">0.350</td>
<td align="right">0.43</td>
<td>1.2K</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLV#NYSE">XLV</a>)</td>
<td>SPDR Select Sector Fund - Health Care</td>
<td align="right">147.0600</td>
<td align="right">0.630</td>
<td align="right">0.43</td>
<td>2.3K</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLK#NYSE">XLK</a>)</td>
<td>SPDR Select Sector Fund - Technology</td>
<td align="right">235.8400</td>
<td align="right">0.970</td>
<td align="right">0.41</td>
<td>7.0K</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLY#NYSE">XLY</a>)</td>
<td>SPDR Select Sector Fund - Consumer Discretionary</td>
<td align="right">219.0300</td>
<td align="right">0.640</td>
<td align="right">0.29</td>
<td>2.6K</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLP#NYSE">XLP</a>)</td>
<td>SPDR Select Sector Fund - Consumer Staples</td>
<td align="right">82.3800</td>
<td align="right">0.200</td>
<td align="right">0.24</td>
<td>9.3K</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLRE#NYSE">XLRE</a>)</td>
<td>Real Estate Select Sector SPDR Fund (The)</td>
<td align="right">42.2900</td>
<td align="right">0.060</td>
<td align="right">0.14</td>
<td>933</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLC#NYSE">XLC</a>)</td>
<td>The Communication Services Select Sector SPDR Fund</td>
<td align="right">103.1300</td>
<td align="right">0.110</td>
<td align="right">0.10</td>
<td>282</td>
</tr>
</tbody>
</table>
No loser in today's Pre-market session. 
<a href="https://pro.benzinga.com/?utm_source=insights">Pulled from Benzinga Pro data</a> the above sector movers alert assists traders in understanding macro-level trends and market variations. Traders will look for sector movers providing information on sectors that are over- or under-performing, deriving these results into investing decisions on exchange-traded funds (ETFs) or individual tickers in those sectors. 
For more information on sector movers, <a href="https://www.benzinga.com/movers">click here</a>.

Sector ETFs

Pre-Market Outlook

ETFs

XLRE

Select Sector SPDR-Consumer Discretionary

Leading And Lagging Sectors For February 24, 2025

<a href="https://www.sec.gov/Archives/edgar/data/1713210/000149315225007977/ex99-1.htm" title="https://www.sec.gov/Archives/edgar/data/1713210/000149315225007977/ex99-1.htm">https://www.sec.gov/Archives/edgar/data/1713210/000149315225007977/ex99-1.htm</a>

ATPC

AGAPE ATP Corp. Signs ICPO With Swiss One Oil & Gas AG For 200,000 MT Of EN590 And 2M Barrels Of Jet Fuel A1

Offerings

LFMD

LifeMD Expands Into the Behavioral Health Market. The Move Broadens LifeMD's Service Offerings To Include Teletherapy, Psychiatry And Medication Management For Common Mental Health Conditions.

Rezolve Ai&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RZLV#NASDAQ">RZLV</a>), the trailblazer in AI-driven commerce solutions, today unveiled a&nbsp;bold&nbsp;$1 billion Bitcoin treasury programme, kickstarting with an initial&nbsp;$100 million investment. This visionary move underscores Rezolve Ai's unwavering commitment to revolutionizing global commerce by seamlessly integrating artificial intelligence, blockchain technology, and cryptocurrency.

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Markets

RZLV

Rezolve Ai Launches $1B Bitcoin Treasury To Fuel The Future Of AI-Powered Crypto Commerce, Kickstarting With An Initial $100M Investment

AMTD IDEA Group American Depositary Shares, each representing six (6) Class A Ordinary Shares

AMTD IDEA

AtlasClear Holdings

Dominari Holdings

Garden Stage

Lion Group Holding Ltd. - American Depositary Share

Lion Group Holding

MDB Capital Holdings, LLC - Class A common

MDB Capital Holdings

Magic Empire Global Limited - Class A Ordinary Shares

Magic Empire Glb

mF International Limited - Class A Ordinary Shares

mF International

Marex Group

Oppenheimer Holdings, Inc. Class A Common Stock (DE)

Oppenheimer Hldgs

Plutus Financial Group Limited - Ordinary Shares

Plutus Financial Group

Perella Weinberg Partners - Class A Common Stock

Perella Weinberg

B. Riley Financial

Siebert Finl

Solowin Holdings - Class A Ordinary Share

Solowin Holdings

UP Fintech Holding Limited - American Depositary Shares representing fifteen Class A Ordinary Shares

Comments

TOP Finl Gr

TOP Finl Gr (TOP) 옵션

No option chain data available. Please try again later

뉴스

파트너 / 기고자

벤징가 글로벌